Skip to content
Forcyte Biotechnologies, Inc

the function-first biology company

Menu
  • Company
    • VISION
    • ABOUT
    • TEAM
    • NEWS
    • CONTACT
  • Platform
    • FLECS TECHNOLOGY
    • PUBLICATIONS
  • Mechanomics
    • MECHANOMIC DISEASES
    • PIPELINE

Author: forcyte

Funding

Forcyte Bio Secures New Funding From Y Combinator & Others, Bringing Total to >$5.7 Million

LOS ANGELES–(BUSINESS WIRE)–Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila (CEO, Golden), …

Funding

Forcyte awarded Phase 2 SBIR by NIH / NCATS to develop pseudo-3D contractile “tissuoid” assay enabling study of coordinated cell contractions and tachyphylaxis

Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs in respiratory, hypertension, and many other indications where cellular force …

New Materials

New App Note covering FLECS Technology in collaboration with Molecular Devices is now available:

The collaborative App Note can be requested directly from Molecular Devices. Inquiries may be directed to info@forcytebio.com. Free assay samples are available! Download App Note Here!

Uncategorized

Forcyte’s Cardiac Tissuoid assay is now available

Conferences

Forcyte Bio to participate in Innovation AveNEW for Startups Showcase at SLAS 2019

Forcyte has been selected as 1 of 8 companies given a presentation space at the Society of Laboratory Automation and Screening annual meeting in Washington D.C. on Feb 4-6. We …

Funding

Forcyte awarded NIH funding for a FLECS-based uterine contractility model

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the …

Funding

Forcyte awarded NIH Funding for a FLECS-based migraine model

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health …

Uncategorized

Forcyte is hiring! Seeking Associate Bioengineer to jumpstart operations in the LA-area

We are seeking a razor-sharp and self-driven ‘A-player’ trained in and stimulated by biotechnology to join the founding team and lead operations in our LA Biomed location! Great opportunity to …

Uncategorized

The team’s flagship work on the FLECS platform published in Nature Biomedical Engineering

>3 years of work and development in the Di Carlo Lab has led to a thorough publication describing the broad capabilities and use-cases for the FLECS platform. On February 8, …

Uncategorized

Dr. Pushkarsky’s perspective describing FLECS is published in ADT

Dr. Pushkarsky presented the team’s overall work on FLECS Technology at the annual SBI2 meeting in San Diego back in September 2017. He was happy to have been awarded the …

Posts navigation

Older posts

Recent Posts

  • Forcyte Bio Secures New Funding From Y Combinator & Others, Bringing Total to >$5.7 Million
  • Forcyte awarded Phase 2 SBIR by NIH / NCATS to develop pseudo-3D contractile “tissuoid” assay enabling study of coordinated cell contractions and tachyphylaxis
  • New App Note covering FLECS Technology in collaboration with Molecular Devices is now available:
  • Forcyte’s Cardiac Tissuoid assay is now available
  • Forcyte Bio to participate in Innovation AveNEW for Startups Showcase at SLAS 2019

Recent Comments

    Archives

    • June 2022
    • September 2019
    • May 2019
    • January 2019
    • July 2018
    • April 2018
    • March 2018
    • November 2017

    Categories

    • Conferences
    • Funding
    • New Materials
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Copyright © 2017 Forcyte Biotechnologies, Inc